Novartis AG
del-brax
f acioscapulohumeral muscular dystrophy (FSHD)
Resolved
7days ago
Phase 3 readout · Jun 30, 2026
What's at stake
Phase 3 trial results for del-brax in f acioscapulohumeral muscular dystrophy (FSHD) are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“FORTITUDE-3 (NCT07038200), a randomized, double-blind, placebo-controlled Phase III study evaluating the efficacy and safety of del-brax, is currently enrolling 200 patients with FSHD aged 16-70 years.”